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The standard of care treatment for patients diagnosed with glioblastoma multiforme (GBM) is
temozolomide (TMZ). Tumour resistance to TMZ results in significantly limited clinical effectiveness.
There is therefore an inherent need for alternatives to TMZ capable of overcoming resistance associated
with MGMT and MMR. In the present study, a series of ester and amide analogues of TMZ, modified at
position 8 on the imidazole ring, were prepared and investigated for antiproliferative properties. It was
found that phenolic ester analogues of TMZ displayed increased potency, of up to 5-fold, against
specified glioblastoma cell lines. The encouraging results displayed by the phenolic TMZ esters
prompted further investigations against patient-derived primary glioblastoma cultures. The primary
cultures, BTNW914 and BTNW374, were MGMT positive and MGMT negative, respectively. Lead phenolic
TMZ esters were found to decrease viability in primary cells at clinically relevant concentrations,
irrespective of MGMT expression. Furthermore, TMZ was found to be ineffective against the same
primary cells at clinically relevant concentrations. The novel phenyl ester analogues of TMZ, described in
this study, could have potential chemotherapeutic properties for the treatment of GBM, overcoming the
resistance associated with the expression of MGMT.Introduction
Glioblastoma multiforme (GBM), a grade IV tumour of astrocytic
lineage, is the most aggressive glioma in adults accounting for
54% of all diagnosed cases.1,2 The most notable advancement in
the treatment of GBM in the past 20 years has been the inclusion
of the alkylating prodrug, temozolomide (TMZ; 3-methyl-4-oxo-
imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide) in the treatment
regimen, resulting in a median survival of 14–15 months.3,4
Prodrug activation of TMZ occurs through hydrolytic degra-
dation at physiological pH forming the cytotoxic methyl-
diazonium ion (Fig. 1). The lipophilic nature of the
imidazotetrazine core of TMZ allows a more efficient penetra-
tion of the blood brain barrier (BBB) compared with other
alkylating agents.5 TMZ elicits its mechanism of action through
the methylation of guanine, forming O6-methyl guanine (O6-
MeG), causing subsequent mismatch with thymine during
replication.6 Futile cycles of insertion and deletion of thymine
are initiated bymismatch repair (MMR) proteins, which persists
until the replication fork collapses, inducing fatal doublece, The University of Central Lancashire,
n@uclan.ac.uk
tion (ESI) available. See DOI:
f Chemistry 2020stranded breaks.7 However, 60% of all newly treated GBM
patients receive no clinical benet from treatment with TMZ
due to resistance and the development of clinically signicant
toxicity, attributed to the high dose regimens resulting in
further treatment being unsafe.8,9 GBM resistance to TMZ
treatment is predominantly a result of the expression of the
suicide O6-MeG repair enzyme, O6-methyl-guanine DNA meth-
yltransferase (MGMT) and the presence of dysfunctional MMR
proteins.10,11
The aim of the present study was to synthesise novel
analogues of TMZ, possessing greater potency than the parent
drug. Earlier publications reported on the modications of imi-
dazotetrazines at position 3 of the molecule, a position that is
known to be directly involved in the mechanism of action.
However, modications at this position result in compounds that
are either inactive or too toxic for clinical use.12 An example of
such a compound was the cross-linking 2-chloroethyl analogue,
mitozolomide.12–14 Interestingly, the amide group present at
position 8 of the imidazole ring is not essential for cytotoxicity of
TMZ and remains as an artefact from its initial synthesis.15
Modications at position 8 have given rise to analogues with
a wide range of activity, however, there is no evidence that
supports a structural activity relationship.15–19 It is hypothesised
that modications at position 8 could play a role in: modifying
the transport properties of the drug; disturbing the interactionsRSC Adv., 2020, 10, 17561–17570 | 17561
Fig. 1 Hydrolytic prodrug activation of TMZ.
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View Article Onlinebetween the inactive prodrug and the DNA; or exerting kinetic
control of the hydrolytic degradation of the prodrug.15,20
In the present study, a series of position 8 modied ester and
amide analogues of TMZ were synthesised, with the aim of
increasing the activity. The modied analogues could provide
the foundations for potential alternatives to TMZ that possess
superior chemotherapeutic activity for the treatment of GBM.
Results and discussion
Chemistry
Ester and amide TMZ analogues were synthesised using two
schemes. The general route of synthesis outlined in Scheme 1
was originally described by Horspool et al., (1990).21 Ester
analogues (3a–3g) and amide analogues (4a–4k) of TMZ were
synthesised through hydrolysis of the TMZ carbomoyl group
using nitrous acid to form TMZ acid 2 (3-methyl-4-oxo-imidazo
[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid). Conversion of TMZ
acid to TMZ acyl chloride (3-methyl-4-oxo-imidazo[5,1-d]
[1,2,3,5]tetrazine-8-carbonyl chloride) was readily achieved
through reux with thionyl chloride, catalysed by VilismeierScheme 1 Synthesis of TMZ analogues. (I) NaNO2, H2SO4, <15 C; (II) SOC
are referred to as 3 and 4, respectively.
17562 | RSC Adv., 2020, 10, 17561–17570iminium salt formation through the addition of dime-
thylformamide. Preferential nucleophilic attack of the imidazo
carbonyl group on TMZ acyl chloride by the various alcohols
and amines, yielded the target analogues.
Unfortunately, reactions between TMZ acyl chloride and
phenyl alcohols resulted in unfavourable yields, mainly attrib-
uted to steric effects. Therefore a combination of the coupling
reagent, EDC$HCl (1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride) and catalyst, DMAP (4-dime-
thylaminopyridine) were used to help overcome these effects
(Scheme 2).22 The water-soluble urea by-product was subse-
quently removed via a simple aqueous work up, yielding ester
analogues (3h–3n).Cytotoxic evaluation
Apoptosis of glioma cells induced by TMZ, occurs at least 120
hours aer treatment.7 Consequently, cells were incubated for
144 hours with specied TMZ analogues in the in vitro investi-
gations in order to obtain more reliable IC50 values.l2, DMF, reflux; (III) R–OH/R–NH2, THF, r.t. Ester and amide analogues
This journal is © The Royal Society of Chemistry 2020
Scheme 2 Synthesis of TMZ analogues. (I) NaNO2, H2SO4, <15 C; (II) EDC$HCl, DMAP, THF : DCM (1 : 1), R–OH/R–NH2, r.t. Ester analogues are
referred to as 3.
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View Article OnlineIn order to assess the cytotoxic potential of the synthesised
TMZ analogues, initial screening was conducted against the
grade IV glioblastoma cell line, U87-MG (Table 1). For TMZ and
TMZ acid the average IC50 was 696  79 and 662  42 mM,
respectively. The equi-cytotoxicity observed between TMZ and
TMZ acid against U87-MG cells was consistent with earlier
published literature using lymphoma cells (TLX9)23 and glioma
cells (TJ899; TJ905 and SHG-44).19 TMZ analogues 3a, 3c, 3g, 3m
and 4b, similar to TMZ acid, exhibited cytotoxicity comparable
to or less than TMZ. Analogue 3g, an analogue originally
described by Liu et al., (2010), was reported to exhibit promising
cytotoxic potential, however, testing did not include glioblas-
toma cell lines, thus providing the rationale of its inclusion in
the present study.18 This analogue was found to be less active
than TMZ and was therefore removed from the investigation.
Although attempts to assess the IC50 of the analogues against
U87-MG were made, a signicant proportion of the amide
analogues and three of the ester analogues, (3d, 3e, 3f, 4a, 4c,
4d, 4e, 4f, 4g, 4h, 4i, 4k) were found to be insoluble in cell
culture medium and were therefore removed from the studies.
The maximum concentration that could be achieved in medium
for amide analogues 4a and 4c was approximately 200 mM, at
which IC50 values could not be generated and were also elimi-
nated from further studies. Interestingly, ester analogues (3b,Table 1 IC50 concentrations (mM) of TMZ analogues against U87-MG
cellsa
Analogue IC50
b (mM) Analogue IC50
b (mM)
TMZ 696  79 3l 331  47
TMZ acid 662  42 3m 576  91
3a 700  109 3n 376  62
3b 409  45 4a >200
3c 615  96 4b 548  48
3d — 4c >200
3e — 4d —
3f — 4e —
3g 856  20 4f —
3h 134  7 4g —
3i 142  3 4h —
3j 96  3 4i —
3k 138  7 4j 139  28
4k —
a All the data were the average values of three independent assays, IC50
 SD (n ¼ 3). b Compound concentration that reduces cell viability by
50% compared to untreated cells.
This journal is © The Royal Society of Chemistry 20203h, 3i, 3j, 3k, 3l, 3n) exhibited 2 to 5-fold greater activity against
the U87-MG cell lines compared to TMZ and were subsequently
taken forward to test against additional cell lines. Interestingly,
the phenyl containing ester analogues 3h, 3i, 3j, 3k, 3l and 3n
were found to be the most effective when tested against the U87-
MG cell line, compared with TMZ. Due to TMZ hexyl ester 3b,
initially described by Suppasansatorn as a compound for topical
treatment of melanoma,19 was reported to exhibit promising
cytotoxic potency against melanoma cells, the analogue was
tested against glioblastoma cell lines. The ester 3b exhibited
signicantly increased cytotoxic potency against U87-MG cells
compared to TMZ (IC50 ¼ 409 mM).
The ester analogues, (3d, 3e, 3f, 4a, 4c, 4d, 4e, 4f, 4g, 4h, 4i,
4k) were found to be insoluble in cell culture medium and were
therefore removed from the studies.
Due to the encouraging cytotoxicity results of analogues 3b,
3h, 3i, 3j, 3k, 3l, and 3n against the U87-MG cell line, further
testing was carried out against 1321-N1, GOS-3 and the normal
SVGp12 cell line in order to gain amore in-depth understanding
of their cytotoxic potency against various grades of glioma, as
well as non-malignant glial cells (Table 2). The most promising
compounds found through the cytotoxic evaluation were the
ester analogues consisting of para-substituted aromatic moie-
ties, containing methoxy, nitro, chloro and nitrile groups (3h,
3i, 3j and 3k), which exhibited activity 4 to 5-fold greater thanTable 2 IC50 concentrations (mM) of lead TMZ analogues against U87-
MG, 1321-N1, GOS-3 and the normal SVGp12 cell linea
Analogue
IC50
b (mM)
U87-MG 1321-N1 GOS-3 SVGp12
TMZ 621  66 783  40 696  16 239  6
TMZ acid 662  42 596  26 504  30 316  2
3b 409  45 269  20 269  6 182  11
3h 134  7 183  1 183  5 44  2
3i 141  3 104  4 91  1 39  2
3j 96  3 118  11 54  4 33  1
3k 137  7 103  7 151  4 36  3
3l 330  47 511  10 691  35 238  6
3n 376  62 238  8 314  38 215  26
4k 138  28 >200 >200 79  6
a All the data were the average values of three independent assays, IC50
 SD (n ¼ 3). b Compound concentration that reduces cell viability by
50% compared to untreated cells.
RSC Adv., 2020, 10, 17561–17570 | 17563
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View Article OnlineTMZ across each of the cell lines used. The introduction of an
ortho-substituted methoxy moiety (analogue 3m) in place of the
corresponding para-substituted methoxy moiety (analogue 3h)
resulted in reduced activity. Additionally, the unsubstituted
phenyl analogue 3l showed less cytotoxic potential than its
substituted counter-parts (3h, 3i, 3j and 3k). Interestingly,
although analogue 3n, containing a methyl moiety in the para-
position, displayed greater activity than analogue 3l, it was
signicantly less active than analogues containing more polar-
ising aromatic substituents.
The mean plasma concentration of TMZ aer oral ingestion
of a 200 mg tablet is between 70–80 mM.24,25 Brain-tumour
concentrations of TMZ are estimated to be approximately 20%
of the plasma concentration, equivalent to a concentration of 15
mM.25,26 However, because TMZ is a prodrug and is not biolog-
ically active until it degrades to AIC and the cytotoxic methyl-
diazonium ion, these concentrations may not accurately reect
the level of the active drug within the region of the tumour.
These levels are likely to be higher than what is observed in
these studies since a mixture of TMZ, MTIC, and methyl-
diazonium ions will be present in the vicinity of the tumour, all
of which have cytotoxic properties or cytotoxic potential.25 An
evaluation of the literature infers that a clinically relevant
concentration of TMZ ranges from approximately 15 to 75 mM.
At the clinically relevant concentrations of 15 and 75 mM,
TMZ was found to reduce the viability of MGMT devoid cells by
approximately 20%. The relatively modest reduction in viability
supports the ndings that patients treated with TMZ gain
a modest therapeutic benet.8 Our results clearly show that
TMZ is only effective against MGMT devoid GBM cells at
concentrations that are not clinically relevant following
a 200 mg m2 oral dose. Interestingly, analogues containing the
methoxy, nitro, choro and nitrile phenyl esters (3h, 3i, 3j and 3k)
generate IC50's at concentrations clinically relevant in the
tumour (<15 mM), thus, suggesting these analogues could have
a potential to generate a signicant clinical effect in patients
suffering from GBM devoid of MGMT, compared to TMZ. The
phenyl ester analogues 3l and 3n were also found to be signif-
icantly more effective than TMZ, inducing a signicant reduc-
tion in viability greater than 50% at 75 mM against MGMTFig. 2 (A) Cell viability of BTNW914 (MGMT) after treatment by TMZ a
trations and incubation for 6 days. (B) Cell Viability of BTNW374 (MGMT
clinically relevant concentrations. Values are reported as the percentage
17564 | RSC Adv., 2020, 10, 17561–17570devoid GBM cells. However, these two analogues were found to
be less potent than the analogues containing highly polarising
groups (3h, 3i, 3j and 3k).
Fig. 2 shows the cytotoxic potency of the most promising
analogues, (3h, 3i, 3j, 3k and 3n) against BTNW374, an MGMT
positive expressed patient derived primary cultures. As expected,
the repair of the cytotoxic O6-methylation by MGMT appeared to
cause TMZ resistance. The MGMT expressing cells also demon-
strated similar resistance to TMZ acid and phenyl ester 3l, sug-
gesting that these analogues possibly generate cytotoxicity via
a similar mechanism to that of TMZ. Interestingly, the 4-methoxy,
4-nitro, 4-chloro, 4-nitrile and p-cresol phenyl esters (3h, 3i, 3j, 3k
and 3n respectively), generated cytotoxicity at 75 mM, independent
of the MGMT status. Since the imidazotetrazine ring remains
unmodied in these analogues, it is plausible to assume that
methylation still contributes to cytotoxicity in TMZ sensitive cells.
Furthermore, it has recently been established thatmodications at
position 8 of the imidazole ring can inuence the rate of prodrug
activation, therefore, it would be reasonable to suggest that
modifying the substituent on the phenyl ester moiety could
possibly effect the rate at which these prodrugs produce methyl
diazonium ions.10,15 However, as these analogues retain activity
against TMZ resistant cells that express, it is plausible to conclude
that an alternate mechanism may be involved, distinct from
methylation. In the experiments using patient derived primary
cultures expressing high levels of MGMT, analogues 3h, 3i, 3j, 3k
and 3n were found to be signicantly more effective compared to
TMZ. This evidence suggests that these analogues should be
further investigated as potential chemotherapeutic agents for the
treatment of GBM, irrespective of the MGMT status of the tumour.The stability of lead phenolic TMZ analogues aer exposure to
porcine liver esterase (PLE)
The hydrolysis was monitored by the decrease in the peak area
of the corresponding TMZ esters, however, due to sensitivity of
the imidazotetrazine ring to pH, the experiments were carried
out at pH 6 to avoid the formation of imidazoles. The validation
of the analytical method also involved investigating the stability
of the imidazotetrazine ring whilst ensuring PLE retainednd phenyl TMZ ester analogues at various clinically relevant concen-
+) after treatment by TMZ and phenyl TMZ ester analogues at various
of viable cells  SD, n ¼ 3.
This journal is © The Royal Society of Chemistry 2020
Table 3 The time taken for PLE to hydrolyse 50% of phenolic TMZ
esters
Analogue 3h 3i 3j 3k 3l 3n
Time taken to hydrolyse 50%
of the ester (minutes)
7.3 4.2 4.1 13.7 3.4 3.2
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View Article Onlinea signicant level of activity. These ndings were in keeping
with the work published by Junge and Heymann (1979), who
found that PLE has a broad pH optima (pH 6–8).27
Results depicted in Table 3 indicate that 50% of each of the
TMZ esters were hydrolysed by PLE in the rst 14 minutes of
exposure. In fact, 50% of TMZ esters containing para-nitro,
chloro, phenyl and tolyl groups (3i, 3j, 3l and 3n), were hydro-
lysed within the rst 4.2 minutes of PLE exposure (Table 3).
TMZ esters containing para-methoxy and nitrile groups (3h and
3k) conferred increased stability, with 50% hydrolysis being
achieved in 7.3 and 13.7 minutes, respectively. The maximum
intracranial concentration of TMZ is reported to be within
a time frame of approximately 2  0.8 hours.26
As a result, it is unlikely that the lead phenolic TMZ esters would
remain intact on reaching the site of a brain tumour, due to the
rapid rate of hydrolysis observed. Thus, it is probable that TMZ
esters would be hydrolysed to TMZ acid and the corresponding
alcohol. Therefore, the increased activity observed in vitro could
potentially be lost. As a result, these ndings pose a question
regarding the effectiveness of all 6 esters in an in vivo setting.
However, despite the obvious challenges the ester bond poses, the
exceptional in vitro activity displayed, irrespective of MGMT
expression by these analogues (3h, 3i, 3j, 3k, 3l and 3n) should be
further investigated.
Experimental
General
All solvents and reagents were used without any further puri-
cation. Reactions were monitored using silica gel coated TLC
plates with uorescent indicator (254 nm). Flash column chro-
matography, used for purication, was carried out using silica gel
purchased from Sigma Aldrich. Specications of the silica gel
were; 60 A˚ pore size, 230–400 mesh particle size and 40–63 mm
particle size. 1H and 13C NMR were recorded on either a Bruker
Fourier 300 (300 MHz) or a Bruker Advanced III 400 (400 MHz)
and interpreted using Mestrenova soware. All chemical shis
are relative to residual solvent peaks (chloroform-d CDCl3, dH-
7.26; dC-77.16); (DMSO-d6, dH-2.50; dC-39.52). J Values are calcu-
lated in Hz. IR spectra were recorded on Nicolet iS10 Spectrom-
eter and interpreted using OMNICs soware. Melting points were
recorded on a Stuart SMP10 melting point apparatus and are
uncorrected. HRMS to 4 dp was obtained by Pharmidex bymeans
of UHPLC-ToF-MS using electrospray ionisation on an Agilent
1290 UHPLC and Agilent 6550 QToF-MS.
Synthesis of 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]
tetrazine-8-carboxylic acid (2)
TMZ 1 (2.00 g, 10.3 mmol) was dissolved in concentrated sul-
phuric acid (16 mL). Sodium nitrite (2.65 g, 38.4 mmol) in waterThis journal is © The Royal Society of Chemistry 2020(10.4 mL) was added dropwise to the solution, keeping the
temperature of the reaction mixture below 15 C. The resulting
mixture was stirred for 16 hours. Ice water (40 mL) was added to
the mixture, precipitating out the desired product. 3-Methyl-4-
oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid (2, TMZ
acid) was collected via ltration before being dried over phos-
phorus pentoxide in a desiccator for 48 hours. Producing
a white solid, 1.36 g (68% yield). Mp 181 C (decomposition); IR
(cm1) 3499 (O–H stretch), 3080 (C–H stretch), 1764 (C]O
stretch, COOH), 1686 (C]O stretch, CONH), 1H NMR (300MHz,
DMSO-d6), dH: 13.40 (bs, 1H, OH), 8.82 (s, 1H, CH), 3.87 (s, 3H,
CH3).
13C NMR (75 MHz, DMSO-d6), dC: 162.28, 139.52, 136.91,
129.52, 128.17, 36.76. HRMS calcd for C6H5N5O3 ([M + Na]
+):
218.0284; found m/z: 218.0293.Synthesis of analogues 3a–3g and 4a–4k
A mixture of TMZ acid (2, 200 mg, 1.03 mmol), thionyl chloride
(5 mL, 69mmol) and DMF (1 drop) was heated under reux for 3
hours. The resulting mixture was evaporated under reduced
pressure. Toluene (3  10 mL) was added and evaporated to
dryness to yield, 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]
tetrazine-8-carbonyl chloride (TMZ acyl chloride), as a brown/
orange solid 218 mg, (99% yield). TMZ acyl chloride (218 mg,
1.02 mmol) was dissolved in tetrahydrofuran (10 mL). A solu-
tion of tetrahydrofuran (2 mL) and the appropriate alcohol or
amine (1.05 mmol) was added dropwise and stirred for 3 hours.
The crude reaction mixture was embedded onto silica, and
subjected to column chromatography using a solvent system of
an appropriate ratio of petroleum ether (40–60 C) to ethyl
acetate, to afford the desired title compounds.
Ethyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]
tetrazine-8-carboxylate (3a). Light orange solid 145.0 mg (79%
yield). Mp. 130 C; IR (cm1) 1716 (C]O stretch, COO), 1623
(C]O stretch, CONH). 1H NMR (300 MHz, DMSO-d6), dH: 8.85
(s, 1H, CH), 4.38 (q, J ¼ 7.1 Hz, 2H, CH2), 3.88 (s, 3H, CH3), 1.33
(t, J ¼ 7.1 Hz, 3H, CH3). 13C NMR (75 MHz, DMSO-d6), dC: 160.9,
139.4, 137.1, 129.8, 127.1, 61.3, 36.9, 14.7. HRMS calcd for
C8H9N5O3 ([M + Na]
+): 246.0598; found m/z: 246.0629.
Hexyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]
tetrazine-8-carboxylate (3b). Yellow solid 81.2 mg (29% yield).
Mp. 76 C; IR (cm1) 3114 (C–H stretch), 2956 (C–H stretch),
2921 (C–H stretch), 2854 (C–H stretch), 1755 (C]O stretch,
COO), 1722 (C]O stretch, CONH). 1H NMR (300 MHz DMSO-
d6), dH: 8.85 (s, 1H, CH), 4.34 (t, J ¼ 7.1 Hz, CH2), 3.88 (s, 3H,
CH3), 1.71 (quint, J ¼ 7.1 Hz, 2H, CH2), 1.53–1.16 (m, 8H,
(CH2)4), 0.87 (t, J ¼ 7.1 Hz, 3H, CH3). 13C NMR (75 MHz DMSO-
d6), dC: 161.0, 139.4, 137.1, 129.8, 127.1, 65.2, 36.8, 31.3, 28.6,
25.5, 22.5, 14.4. HRMS calcd for C12H17N5O3 ([M + Na]
+):
302.1224; found m/z: 302.1239.
Phenethyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]
tetrazine-8-carboxylate (3c). Off-white solid 177.4 mg (44%
yield). Mp 124 C; IR (cm1) 3067 (C–H stretch), 1740 (C]O
stretch, COO), 1712 (C]O stretch, CONH). 1H NMR (300 MHz
DMSO-d6), dH: 8.85 (s, 1H, CH), 7.38–7.19, (m, 5H, ArH), 4.55 (t, J
¼ 7.5 Hz, 2H, CH2), 3.89 (s, 3H, CH3), 3.05 (t, J ¼ 7.5 Hz, 2H,
CH2).
13C NMR (75 MHz DMSO-d6), dC: 160.9, 139.4, 138.4,RSC Adv., 2020, 10, 17561–17570 | 17565
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View Article Online137.2, 129.8, 129.5, 128.8, 126.9, 126.9, 65.8, 36.9, 34.9. HRMS
calcd for C14H13N5O3 ([M + Na]
+): 322.0911; found m/z:
322.0925.
4-Nitrophenethyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d]
[1,2,3,5]tetrazine-8-carboxylate (3d). White solid 102.6 mg
(27% yield). Mp 187 C; IR (cm1) 3105 (C–H stretch), 1743 (C]
O stretch, COO), 1708 (C]O stretch, CONH). 1H NMR (300
MHz, DMSO-d6), dH: 8.86 (s, 1H, CH), 8.15 (d, J ¼ 8.3 Hz, 2H,
ArH), 7.67 (d, J ¼ 8.3 Hz, 2H, ArH), 4.63 (t, J ¼ 6.4 Hz, 2H, CH2),
3.90 (s, 3H, CH3), 3.22 (t, J¼ 6.4 Hz, 2H, CH2). 13C NMR (75MHz
DMSO-d6), dC: 160.7, 147.0, 146.7, 139.4, 137.2, 130.9, 129.9,
126.7, 123.8, 65.0, 36.9, 34.6. HRMS calcd for C14H12N6O3 ([M +
Na]+): 367.0761; found m/z: 367.0772.
4-Methoxyphenethyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-
d][1,2,3,5]tetrazine-8-carboxylate (3e). Off-white solid 79 mg
(22% yield). Mp 164 C; IR (cm1) 3126 (C–H stretch), 1745 (C]
O stretch, COO), 1725 (C]O stretch, CONH). 1H NMR (300
MHz, DMSO-d6), dH: 8.85 (s, 1H, CH), 7.27 (d, J ¼ 8.4 Hz, 2H,
ArH), 6.85 (d, J ¼ 8.4 Hz, 2H, ArH), 4.48 (t, J ¼ 6.8 Hz, 2H, CH2),
3.89 (s, 3H, CH3), 3.71 (s, 3H, CH3), 2.98 (t, J ¼ 6.8 Hz, 2H, CH2).
13C NMR (75 MHz DMSO-d6), dC: 160.9, 158.3, 139.4, 137.2,
130.5, 130.1, 129.8, 127.0, 114.2, 66.1, 55.4, 36.9, 34.0. HRMS
calcd for C15H15N5O4 ([M + Na]
+): 352.1016; found m/z:
352.1029.
4-Methoxybenzyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d]
[1,2,3,5]tetrazine-8-carboxylate (3f). Yellow solid 111.4 mg
(37% yield); mp 170 C, IR (cm1) 3122 (C–H stretch), 2961 (C–H
stretch), 2928 (C–H stretch), 1752 (C]O stretch, COO), 1719
(C]O stretch, CONH). 1H NMR (300 MHz, DMSO-d6), dH: 8.85
(s, 1H, CH), 7.44 (d, J¼ 8.4 Hz, 2H, ArH), 6.96 (d, J ¼ 8.4 Hz, 2H,
ArH), 5.36 (s, 2H, CH2), 3.88 (s, 3H, CH3), 3.76 (s, 3H, CH3).
13C
NMR (75 MHz DMSO-d6), dC: 160.8, 159.7, 139.4, 137.3, 130.5,
129.9, 128.3, 126.9, 114.3, 66.4, 55.6, 36.9. HRMS calcd for
C14H13N5O4 ([M + Na]
+): 338.0860; found m/z: 338.8075.
3-(Dimethylamino)propyl 3-methyl-4-oxo-3,4-dihy-
droimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate (3g). White
solid 132.4 mg (46% yield). Mp 204 C, IR (cm1) 3074 (C–H),
2595–2483 (C–H), 1747 (C]O stretch, COO), 1719 (C]O
stretch, CONH), 1615–692. 1H NMR (300 MHz, DMSO-d6) dH:
8.89 (s, 1H, CH), 4.43 (t, J ¼ 6.2 Hz, 2H, CH2), 3.89 (s, 3H, CH3),
3.20(t, J ¼ 6.2 Hz, 2H, CH2), 2.75 (s, 6H, CH3), 2.18 (quint, J ¼
6.2 Hz, 2H, CH2).
13C NMR (100 MHz, DMSO) dC: 160.2, 138.9,
136.8, 129.4, 126.3, 62.1, 53.8, 42.1, 36.4, 23.3. HRMS calcd for
C14H13N5O4 ([M + H]
+): 281.1357; found m/z: 281.1372.
N-Hexyl-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]
tetrazine-8-carboxamide (4a). Off-white solid 156.5 mg (55%
yield). Mp 138 C; IR (cm1), 3295 (N–H stretch), 3118 (C–H
stretch), 2921 (C–H stretch), 2856 (C–H stretch), 1726 (C]O
stretch, CONH), 1652 (C]O stretch, CONH). 1H NMR (400MHz,
chloroform-d), dH: 8.40 (s, 1H, CH), 7.35 (t, J ¼ 6.5 Hz, 1H, NH),
4.04 (s, 3H CH3), 3.51 (q, J ¼ 6.5 Hz, 2H, CH2), 1.63 (quint, J ¼
6.5 Hz, 2H, CH2), 1.46–1.27 (m, 6H, (CH2)3), 0.89 (t, J ¼ 6.5 Hz,
3H, CH3).
13C NMR (100 MHz chloroform-d), dC: 159.3, 138.8,
133.7, 132.1, 127.7, 39.4, 36.5, 31.5, 29.5, 22.53, 14.0. HRMS
calcd for C12H18N6O2 ([M + Na]
+): 301.1384; found m/z:
301.1409.17566 | RSC Adv., 2020, 10, 17561–175703-Methyl-4-oxo-N-phenethyl-3,4-dihydroimidazo[5,1-d]
[1,2,3,5]tetrazine-8-carboxamide (4b). Off-white solid 169.2 mg
(58% yield). Mp 158 C; IR (cm1) 3312 (N–H stretch), 3082 (C–H
stretch), 1745 (C]O stretch, CONH), 1646 (C]O stretch,
CONH). 1H NMR (400 MHz, DMSO-d6), dH: 8.84 (s, 1H, CH), 8.54
(t, J¼ 5.9 Hz, 1H, NH), 7.36–7.16 (m, 5H, ArH), 3.87 (s, 3H, CH3),
3.54 (q, J ¼ 7.4 Hz, 2H, CH2), 2.87 (t, J ¼ 7.4 Hz, 2H, CH2). 13C
NMR (100 MHz DMSO-d6), dC: 160.0, 139.8, 139.7, 134.9, 130.8,
129.1, 128.9, 128.8, 126.6, 40.6, 36.6, 35.6. HRMS calcd for
C14H14N6O2 ([M + Na]
+): 321.1071; found m/z: 321.1088.
3-Methyl-4-oxo-N-phenyl-3,4-dihydroimidazo[5,1-d][1,2,3,5]
tetrazine-8-carboxamide (4c). Light orange solid 110.3 mg (40%
yield). Mp 189 C; IR (cm1) 3356 (N–H stretch), 3118 (C–H
stretch), 1734 (C]O stretch, CONH), 1684 (C]O stretch,
CONH). 1H NMR (300 MHz, DMSO-d6), dH: 10.40 (s, 1H, NH),
8.96 (s, 1H, CH), 7.88 (d, J¼ 6.0 Hz, 2H, ArH), 7.36 (t, J¼ 6.0 Hz,
2H, ArH), 7.15 (t, J ¼ 6.0 Hz, 1H, ArH), 3.89 (s, 3H, CH3). 13C
NMR (75 MHz, DMSO-d6), dC: 158.8, 139.6, 138.9, 135.6, 130.6,
129.1, 129.0, 124.4, 120.7, 36.7. HRMS calcd for C12H10N6O2 ([M
+ Na]+): 293.0757; found m/z: 293.0772.
N-(4-Methoxyphenyl)-3-methyl-4-oxo-3,4-dihydroimidazo
[5,1-d][1,2,3,5]tetrazine-8-carboxamide (4d). Yellow solid
75.6 mg (25% yield). Mp 192 C; IR (cm1) 3376 (N–H stretch),
3119 (C–H stretch), 2937 (C–H stretch), 1746 (C]O stretch,
CONH), 1684 (C]O stretch, CONH). 1H NMR (300 MHz, DMSO-
d6), dH: 10.30 (s, 1H, NH), 8.95 (s, 1H, CH), 7.79 (d, J ¼ 9.1 Hz,
2H, ArH), 6.94 (d, J¼ 9.1 Hz, 2H, ArH), 3.89 (s, 3H, CH3), 3.75 (s,
3H, CH3).
13C NMR (75 MHz, DMSO-d6), dC: 158.4, 156.1, 139.7,
135.5, 132.0, 130.8, 128.9, 122.3, 114.2, 55.6, 36.7. HRMS calcd
for C13H12N6O3 ([M + Na]
+): 323.0863; found m/z: 323.0877.
N-(4-Chlorophenyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-
d][1,2,3,5]tetrazine-8-carboxamide (4e). Brown solid 140.7 mg
(45% yield). Mp 200 C; IR (cm1) 3359 (N–H stretch), 3117 (C–H
stretch), 1737 (C]O stretch, CONH), 1689 (C]O stretch,
CONH). 1H NMR (400 MHz, DMSO-d6), dH: 10.59 (s, 1H, NH),
8.97 (s, 1H, CH), 7.93 (d, J¼ 8.8 Hz, 2H, ArH), 7.42 (d, J¼ 8.8 Hz,
2H, ArH), 3.90 (s, 3H, CH3).
13C NMR (100 MHz, DMSO-d6), dC:
158.4, 139.1, 137.4, 135.3, 129.8, 128.5, 127.5, 121.8, 36.2. HRMS
calcd for C12H9N6O2Cl ([M + Na]
+): 327.0368; found m/z:
327.0382.
N-(4-Cyanophenyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-
d][1,2,3,5]tetrazine-8-carboxamide (4f). Off-white solid 216.0 mg
(73% yield). Mp 234 C; IR (cm1) 3339 (N–H stretch), 3117 (C–H
stretch), 2222 (C^N stretch), 1740 (C]O stretch, CONH), 1689
(C]O stretch, CONH). 1H NMR (400 MHz, DMSO-d6), dH: 10.75
(s, 1H, NH), 8.93 (s, 1H, CH), 8.10 (d, J ¼ 8.8 Hz, 2H, ArH), 7.81
(d, J ¼ 8.8 Hz 2H, ArH), 3.90 (s, 3H, CH3). 13C NMR (100 MHz,
DMSO-d6), dC: 158.8, 142.7, 139.0, 135.5, 133.0, 129.5, 128.6,
120.3, 118.9, 105.7, 36.2. HRMS calcd for C13H9N7O2 ([M + Na]
+):
318.0710; found m/z: 318.0720.
3-Methyl-4-oxo-N-(p-tolyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]
tetrazine-8-carboxamide (4g). Yellow solid 164.7 mg (58%). Mp
209 C; IR (cm1) 3301 (N–H stretch), 3114 (C–H stretch), 1735
(C]O stretch, CONH), 1672 (C]O stretch, CONH). 1H NMR
(400 MHz, DMSO-d6) dH: 10.30 (s, 1H, NH), 8.94 (s, 1H, CH), 7.75
(d, J¼ 8.8 Hz, 2H, ArH), 7.16 (d, J¼ 8.8 Hz, 2H, ArH), 3.89 (s, 3H,This journal is © The Royal Society of Chemistry 2020
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View Article OnlineCH3), 2.28 (s, 3H, CH3).
13C NMR (100 MHz, DMSO) dC: 158.6,
139.6, 136.4, 135.5, 133.4, 130.7, 129.5, 128.9, 120.7, 36.7, 21.0.
HRMS calcd for C13H12N6O2 ([M + Na]
+): 307.0914; found m/z:
307.0929.
N-(2-Methoxyphenyl)-3-methyl-4-oxo-3,4-dihydroimidazo
[5,1-d][1,2,3,5]tetrazine-8-carboxamide (4h). Yellow solid
268.7 mg (87%). Mp 193 C; IR (cm1) 3370 (N–H stretch), 1741
(C]O stretch, CONH), 1677 (C]O stretch, CONH). 1H NMR
(400 MHz, DMSO-d6) dH: 9.78 (s, 1H, NH), 8.95 (s, 1H, CH), 8.40
(d, J ¼ 8.8 Hz, 1H, ArH), 7.14 (d, J ¼ 8.8 Hz, 2H, ArH), 7.01 (m,
1H, ArH), 3.94 (s, 3H, CH3), 3.90 (s, 3H, CH3).
13C NMR (100
MHz, DMSO) dC: 157.6, 148.8, 139.5, 135.4, 130.0, 129.2, 127.5,
124.7, 121.2, 119.6, 111.6, 56.6, 36.8. HRMS calcd for
C13H12N6O3 ([M + Na]
+): 323.0863. Found m/z: 323.0878.
N-(4-Methoxybenzyl)-3-methyl-4-oxo-3,4-dihydroimidazo
[5,1-d][1,2,3,5]tetrazine-8-carboxamide (4i). Off-white solid
199.7 mg (60% yield). Mp 193 C. IR (cm1) 3371 (N–H stretch),
3126 (C–H stretch), 1735 (C]O stretch, CONH), 1696 (C]O
stretch, CONH). 1H NMR (400 MHz, DMSO-d6) dH: 8.99 (t, J ¼
6.3 Hz, 1H, NH), 8.85 (s, 1H, CH), 7.27 (d, J ¼ 8.8 Hz, 2H, ArH),
6.88 (d, J ¼ 8.8 Hz, 2H, ArH), 4.42 (d, J ¼ 6.3 Hz, 2H, CH2), 3.86
(s, 3H, CH3), 3.72 (s, 3H, CH3).
13C NMR (100 MHz, DMSO) dC:
159.5, 158.1, 139.1, 134.5, 131.5, 130.3, 128.7, 128.4, 113.6, 55.0,
41.5, 36.1. HRMS calcd for C14H14N6O3 ([M + Na]
+): 337.1020;
found m/z: 337.1038.
3-Methyl-N-(4-methylbenzyl)-4-oxo-3,4-dihydroimidazo[5,1-
d][1,2,3,5]tetrazine-8-carboxamide (4j). Off-white solid 168.5 mg
(54% yield); mp 152 C. IR (cm1) 3397 (N–H stretch), 3102 (C–H
stretch), 1736 (C]O stretch, CONH), 1665 (C]O stretch,
CONH). 1H NMR (400MHz, DMSO-d6) dH: 9.01 (t, J¼ 6.4 Hz, 1H,
NH), 8.86 (s, 1H, CH), 7.22 (d, J ¼ 4.0 Hz, 2H, ArH), 7.12 (d, J ¼
4.0 Hz, 2H, ArH), 4.44 (d, J¼ 6.4 Hz, 2H, CH2), 3.86 (s, 3H, CH3),
2.27 (s, 3H, CH3).
13C NMR (100 MHz, DMSO) dC: 159.6, 139.1,
136.5, 135.7, 134.5, 130.3, 128.7, 128.4, 127.3, 41.8, 36.1, 20.6.
HRMS calcd for C14H14N6O2 ([M + Na]
+): 321.1071; found m/z:
321.1090.
N-(4-Chlorobenzyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-
d][1,2,3,5]tetrazine-8-carboxamide (4k). Off-white solid
154.3 mg (47% yield). Mp 148 C. IR (cm1) – 3288 (N–H
stretch), 1735 (C]O stretch, CONH), 1651 (C]O stretch,
CONH). 1H NMR (400MHz, DMSO-d6) dH: 9.15 (t, J¼ 6.3 Hz, 1H,
NH), 8.87 (s, 1H, CH), 7.41–7.33 (m, 4H, ArH), 4.47 (d, J¼ 6.3 Hz,
2H, CH2), 3.87 (s, 3H, CH3).
13C NMR (100 MHz, DMSO) dC:
159.7, 139.1, 138.6, 134.6, 131.3, 130.1, 129.2, 128.5, 128.1, 41.4,
36.1. HRMS calcd for C13H11N6O2Cl ([M + Na]
+): 341.0524; found
m/z: 341.0542.Synthesis of analogues 3h–3n
TMZ acid (2, 200 mg, 1.03 mmol) was solubilised in mixture of
THF and DCM (10 mL : 10 mL v/v). The desired alcohol was
added (1.05 mmol) dropwise to the solution. The mixture was
then stirred for 10 minutes. A solution of EDC$HCl (305 mg,
1.60 mmol) in DCM (2 mL) was added along with DMAP (1 mg).
The reaction was stirred for 3 hours. The crude reaction mixture
was embedded onto silica and subjected to ash column
chromatography using a solvent system of an appropriate ratioThis journal is © The Royal Society of Chemistry 2020of petroleum ether (40–60 C) to ethyl acetate, to remove excess
alcohol. The product was solubilised in DCM (20 mL) and
washed with water (3  30 mL) and brine (30 mL). The DCM
layer was dried over sodium sulphate and the solvent was
evaporated under reduced pressure to afford the desired title
compounds.
4-Methoxyphenyl 3-methyl-4-oxo-3,4-dihydroimidazo [5,1-d]
[1,2,3,5] tetrazine-8-carboxylate (3h). Off-white solid 489.8 mg
(50% yield). Mp 172 C; IR (cm1) 3117 (C–H stretch), 1739 (C]
O stretch)*. 1H NMR (300 MHz, DMSO-d6), dH: 8.96, (s, 1H, CH),
7.22 (d, J ¼ 9.0 Hz, 2H, ArH), 7.03 (d, J ¼ 9.0 Hz, 2H, ArH), 3.92
(s, 3H, CH3), 3.79 (s, 3H, CH3).
13C NMR (75 MHz DMSO-d6), dC:
159.0, 157.5, 143.8, 138.5, 136.3, 128.8, 128.6, 122.3, 114.5, 55.6,
36.8. HRMS calcd for C13H11N5O4 ([M + Na]
+): 324.0703; found
m/z: 324.0713. *Overlap of COO ester carbonyl and CO urea
carbonyl.
4-Nitrophenyl 3-methyl-4-oxo-3,4-dihydroimidazo [5,1-d]
[1,2,3,5] tetrazine-8-carboxylate (3i). White solid 488.1 mg (49%
yield). Mp 190 C, IR (cm1) 3154 (C–H stretch), 3114 (C–H
stretch), 1754 (C]O stretch, COO), 1727 (C]O stretch, CONH).
1H NMR (300 MHz, DMSO-d6), dH: 8.98 (s, 1H, CH), 8.38 (d, J ¼
9.0 Hz, 2H, ArH), 7.66 (d, J¼ 9.0 Hz, 2H, ArH), 3.94 (s, 3H, CH3).
13C NMR (75 MHz DMSO-d6), dC: 158.6, 155.3, 145.8, 139.3,
138.3, 130.4, 126.0, 125.2, 123.7, 37.1. HRMS calcd for
C12H8N6O5 ([M + Na]
+): 339.0448; found m/z: 339.0460.
4-Chlorophenyl 3-methyl-4-oxo-3,4-dihydroimidazo [5,1-d]
[1,2,3,5] tetrazine-8-carboxylate (3j). White solid 442.3 mg (44%
yield). Mp 164 C; IR (cm1) 3089 (C–H stretch), 1733 (C]O
stretch)*. 1H NMR (400 MHz, DMSO-d6), dH: 8,97 (s, 1H CH),
7.56 (d, J ¼ 9.0 Hz, 2H, ArH), 7.38 (d, J ¼ 9.0 Hz, 2H, ArH), 3.93
(s, 3H, CH3).
13C NMR (100 MHz DMSO-d6), dC: 158.7, 148.8,
138.8, 137.5, 130.3, 129.8, 129.6, 125.2, 123.7, 36.6. HRMS calcd
for C12H8N5O3Cl ([M + Na])
+: 328.0208; found m/z: 328.0219.
*Overlap of COO ester carbonyl and CO urea carbonyl.
4-Cyanophenyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d]
[1,2,3,5]tetrazine-8-carboxylate (3k). White solid 287.8 mg
(30% yield). Mp 192 C; IR (cm1) 3146 (C–H stretch), 3110 (C–H
stretch), 2224 (C^N stretch), 1759 (C]O stretch, COO), 1730
(C]O stretch, CONH). 1H NMR (300 MHz, DMSO-d6), dH: 9.00
(s, 1H, CH), 8.01 (d, J¼ 8.8 Hz, 2H, ArH), 7.58 (d, J ¼ 8.8 Hz, 2H,
ArH), 3.93 (s, 3H CH3).
13C NMR (75 MHz DMSO-d6), dC: 158.2,
153.4, 138.8, 137.7, 134.2, 129.9, 124.8, 123.30, 118.3, 109.1,
36.6. HRMS calcd for C13H8N6O3 ([M + Na]
+): 319.0550; foundm/
z: 319.0550.
Phenyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]
tetrazine-8-carboxylate (3l). Off-white solid 75.3 mg (27%
yield). Mp 149 C; IR (cm1) 3143 (C–H stretch), 1737 (C]O
stretch)*. 1H NMR (400 MHz, chloroform-d), dH: 8.53 (s, 1H,
CH), 7.51–7.37 (m, 2H, ArH), 7.35–7.23 (m, 3H, ArH), 4.06 (s, 3H,
CH3).
13C NMR (100 chloroform-d), dC: 158.7, 150.2, 138.4,
136.3, 129.5, 128.8, 128.4, 126.3, 121.5, 36.8. HRMS calcd for
C12H9N5O3 ([M + Na]
+): 294.0597; foundm/z: 294.0606. *Overlap
of COO ester carbonyl and CO urea carbonyl.
2-Methoxyphenyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d]
[1,2,3,5]tetrazine-8-carboxylate (3m). Orange solid 150.7 mg
(49% yield). Mp 165 C; IR (cm1) 3153 (C–H stretch), 1737 (C]
O stretch)*. 1H NMR (400 MHz, DMSO-d6), dH: 8.95 (s, 1H, CH),RSC Adv., 2020, 10, 17561–17570 | 17567
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View Article Online7.31 (t, J ¼ 7.6 Hz, 1H, ArH), 7.23 (ddd, J ¼ 7.6, 8.2, 1.6 Hz, 2H,
ArH), 7.04 (t, J ¼ 7.6 Hz, 1H, ArH), 3.92 (s, 3H, CH3), 3.77 (s, 3H,
CH3).
13C NMR (100 MHz DMSO-d6), dC: 158.3, 150.8, 138.9,
137.4, 129.7, 127.3, 125.3, 122.8, 120.7, 112.9, 56.0, 36.5. HRMS
calcd for C13H11N5O4 ([M + Na]
+): 324.0703; found m/z:
324.0715. *Overlap of COO ester carbonyl and CO urea
carbonyl.
p-Tolyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]
tetrazine-8-carboxylate (3n). Off-white solid 81.5 mg (28%
yield). Mp 164 C; IR (cm1) 3122 (C–H stretch), 1734 (C]O
stretch)*. 1H NMR (400 MHz, chloroform-d) dH: 8.51 (s, 1H, CH),
7.22 (d, J ¼ 8.0 Hz, 2H, ArH), 7.17 (d, J ¼ 8.0 Hz, 2H, ArH), 4.05
(s, 3H, CH3), 2.37 (s, 3H, CH3).
13C NMR (100 MHz, CDCl3) dC:
158.8, 148.0, 138.4, 136.3, 136.0, 130.0, 128.8, 128.5, 121.2, 36.7,
21.0. HRMS calcd for C13H11N5O3 ([M + Na]
+): 308.0754; found
m/z: 308.0764. *Overlap of COO ester carbonyl and CO urea
carbonyl.Cell lines, primary cells and culture conditions
Cytotoxic evaluation of the analogues was completed against 4
cell lines and 2 primary GBM cultures. The human glioma cell
lines, GOS-3, U87-MG and 1321-N1 along with the human
astroglial cell line, SVGp12, were purchased from The European
Collection of Cell Cultures (ECCAC, UK) and Deutsche Samm-
lung vonMikroorganismen und Zellkulturen (DMSZ, Germany).
Patient derived primary GBM cultures, BTNW374 and
BTNW914, were obtained from The Brain Tumour North West
Tissue Bank in collaboration with The Royal Preston Hospital.
Patient data for primary cells was included as part of the ESI.†
1321-N1 (human astrocytoma) was maintained in DMEM
medium supplemented with 2 mM L-glutamine and 10% FBS.
GOS-3, (human brain mixed astro-oligodendroglioma) wasFig. 3 Chromatogram indicating the retention times of TMZ acid and
(sodium acetate buffer (20 mM) : acetonitrile 60 : 40, v/v, pH 4.5).
17568 | RSC Adv., 2020, 10, 17561–17570maintained in DMEM medium supplemented with 2 mM L-
glutamine and 10% fetal bovine serum albumin. U87-MG,
(human glioblastoma) and SVGp12 (normal human astroglia)
were maintained in EMEMmedium supplemented with 2mM L-
glutamine, 1 mM sodium pyruvate and 10% FBS. All cell lines
were incubated at 37 C and 5% CO2 in a humidied incubator.
Primary BTNW cultures were maintained in Ham's F10 nutrient
mixture, containing 20 mM HEPES, 2 mM glutamine and 10%
FBS. Primary cultures were incubated in a humidied incubator
at 37 C.CellTiter-Glo® assay
Cells were seeded in the appropriate media in each well of
a Costar 96-well plate at a density of 5  102 immortalised cells;
2  103 (primary cells). The plates were incubated at 37 C and
5% CO2 in a humidied incubator for 24 hours to allow cells to
adhere. Each of the drugs tested were dissolved in DMSO to
afford a 200 mM stock solution. The stock solutions were
diluted withmedium to afford the nal working concentrations,
ensuring DMSO concentration was no greater than 0.5% (v/v).
Drug concentrations were added to the cells and incubated
for 144 hours. Aer incubation, the drug concentrations were
removed and replaced with 100 mL of CellTiter-Glo® and 100 mL
of media. The luminescence of each well was measured on
GENios Pro plate reader. The results for each of the drug
concentrations were expressed as a percentage of the control
wells. For cell lines, the regression equation for a polynomial
line of best t of order 2 was used to calculate the IC50. In the
case of the in vitromodel used in the present study, the IC50 was
dened as the concentration of drug that results in a 50%
reduction in oxyluciferin production. Primary culture cells were
incubated with clinically relevant concentrations for 144 hours.ester analogues of TMZ 3h, 3i, 3j, 3k, 3l and 3n analysed using HPLC
This journal is © The Royal Society of Chemistry 2020
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View Article OnlineViability was expressed as a percentage of the control wells.
Each experiment involving cell lines was carried out in triplicate
of triplicates. Experiments using patient derived primary
cultures were carried out in triplicate.
Initial screening of the 25 analogues was completed using
the U87-MG cell line. The most promising analogues from the
initial screening were taken forward and tested against the
1321-N1, GOS-3 and SVG-p12 cell lines. The results of all 4 cell
lines were compiled and the analogues that were deemed to be
the most promising drug candidates were tested against
primary cultures at clinically relevant concentrations.General protocol for monitoring the stability of lead phenolic
TMZ analogues on exposure to porcine liver esterase
A disodium phosphate, citric acid buffer (pH 6) was prepared by
using disodium phosphate (Na2HPO4$12H2O, 200 mM) and
citric acid (100 mM). A stock solution of 80 mg/100 mL of each
of the TMZ esters (3h, 3i, 3j, 3k, 3l and 3n) were prepared in
DMSO. The control reaction, without enzyme, was prepared by
adding 3000 mL of buffer to the reaction vessel along with 56.25
mL of the stock solution. The test reaction, with enzyme, was
prepared by adding 2999 mL of buffer to the reaction vessel
along with 56.25 mL of TMZ ester. The nal concentration of
TMZ esters in the reaction vessels was 1.47 mg/100 mL. Porcine
liver esterase (1 mL) was added to the test reaction at zero time
(minutes). Both the control and test reactions were then incu-
bated at 37 C. Aliquots of 200 mL were transferred from the
reaction vessels to 2 mL Eppendorf tubes, at 3 minute intervals
for 30 minutes. The reaction was quenched by adding 200 mL of
acetonitrile. The resulting samples were diluted with mobile
phase and transferred to HPLC vials before analysis.
The chromatographic conditions: RP-HPLC, the mobile
phase consisted of 60% sodium acetate buffer (20 mM) and 40%
acetonitrile (pH 4.5). Analysis was performed at 1 mLmin1 at
ambient temperature on a Waters Symmetry Shield RP C18
column (4.6 mm  250 mm), containing particles equivalent 5
micron. Detection of TMZ acid and TMZ esters (3h, 3i, 3j, 3k, 3l
and 3n) was carried out at 325 nm. Detection of 4-methox-
yphenol and 4-chlorophenol was carried out at 225 nm. Detec-
tion of 4-nitrophenol, 4-hydroxybenzonitrile, phenol and p-
cresol was carried out at 325 nm, 250 nm, 270 nm and 225 nm,
respectively (Fig. 3).Conclusion
The present work reports on an exciting series of phenyl ester
TMZ analogues which possess enhanced cytotoxic potency
against specied glioma and primary GBM cells. The para-
substituted phenyl esters elicit signicant cytotoxicity irre-
spective of MGMT expression in TMZ resistant patient derived
primary cultures. The activity observed against MGMT
expressing primary cultures led to the assumption that these
analogues could possibly generate cytotoxicity via a mechanism
of action distinct from methylation, however, this hypothesis
needs to be further explored. Although this work is very much in
its infancy, we believe that these analogues have the potential toThis journal is © The Royal Society of Chemistry 2020act as superior chemotherapeutic agents for the treatment of
GBM, eliciting a greater therapeutic response, compared to TMZ
in a wider range of patients. The next stage in the investigation
of the most promising analogues will centre around the use of
an in vivo model to further assess their effectiveness. These
investigations will initially focus on the bio-distribution and
BBB evaluation before proceeding in assessing them against in
vivo GBM.
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